FDA Requires New GLP-1 Drug Warnings About a Potential Risk of Rare but Permanent Vision Loss

reinforce the new warning each time a prescription is filled or a patient switches from one GLP-1 RA to another.

Counseling that highlights modifiable risk factors can also be helpful. Although the FDA’s communication centers on medication labeling, the overlapping risks of smoking, uncontrolled hypertension, and unmanaged sleep apnea are clinically important in their own right. Patients may appreciate understanding that some of the same steps that protect their cardiovascular health and diabetes control can also reduce their baseline risk of eye complications. Clear explanations about the rarity of NAION,

Leave a Reply

Your email address will not be published. Required fields are marked *